Dynamics of tumor-specific cfDNA in response to therapy in
multiple myeloma patients

J 2020

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

VRÁBEL, Dávid, Lenka SEDLARIKOVA, Lenka BESSE, Lucie ŘÍHOVÁ, Renata BEZDEKOVA et. al.

Basic information

Original name

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

Authors

VRÁBEL, Dávid (703 Slovakia, belonging to the institution), Lenka SEDLARIKOVA (203 Czech Republic), Lenka BESSE (203 Czech Republic), Lucie ŘÍHOVÁ (203 Czech Republic), Renata BEZDEKOVA (203 Czech Republic), Martina ALMÁŠI (203 Czech Republic), Veronika KUBACZKOVÁ (203 Czech Republic, belonging to the institution), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Hana PLONKOVA (203 Czech Republic), Tomas JELINEK (203 Czech Republic), Viera SANDECKA (203 Czech Republic), Martin STORK (203 Czech Republic), Luděk POUR (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Roman HAJEK (203 Czech Republic)

Edition

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2020, 0902-4441

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.997

RIV identification code

RIV/00216224:14110/20:00115336

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/ejh.13358

UT WoS

000503619400001

Keywords in English

cell-free DNA; liquid biopsy; multiple myeloma; qPCR

Abstract

V originále

Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. Methods While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. Results We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. Conclusions These results support the concept of tumor-specific cell-free DNA as a prognostic marker.

Links

MUNI/A/1553/2018, interní kód MU

Name: Genetické, environmentální a tkáňové charakteristiky vybraných patologických stavů a nemocí (Acronym: genetika; stres; biomateriály; tkáňové kultury)

Investor: Masaryk University, Category A

NV17-29343A, research and development project

Name: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

VRÁBEL, Dávid, Lenka SEDLARIKOVA, Lenka BESSE, Lucie ŘÍHOVÁ, Renata BEZDEKOVA, Martina ALMÁŠI, Veronika KUBACZKOVÁ, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Hana PLONKOVA, Tomas JELINEK, Viera SANDECKA, Martin STORK, Luděk POUR, Sabina ŠEVČÍKOVÁ and Roman HAJEK. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2020, vol. 104, No 3, p. 190-197. ISSN 0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13358.

@article{1623778,
   author = {Vrábel, Dávid and Sedlarikova, Lenka and Besse, Lenka and Říhová, Lucie and Bezdekova, Renata and Almáši, Martina and Kubaczková, Veronika and Brožová, Lucie and Jarkovský, Jiří and Plonkova, Hana and Jelinek, Tomas and Sandecka, Viera and Stork, Martin and Pour, Luděk and Ševčíková, Sabina and Hajek, Roman},
   article_location = {Hoboken},
   article_number = {3},
   doi = {http://dx.doi.org/10.1111/ejh.13358},
   keywords = {cell-free DNA; liquid biopsy; multiple myeloma; qPCR},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients},
   url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358},
   volume = {104},
   year = {2020}
}

TY  - JOUR
ID  - 1623778
AU  - Vrábel, Dávid - Sedlarikova, Lenka - Besse, Lenka - Říhová, Lucie - Bezdekova, Renata - Almáši, Martina - Kubaczková, Veronika - Brožová, Lucie - Jarkovský, Jiří - Plonkova, Hana - Jelinek, Tomas - Sandecka, Viera - Stork, Martin - Pour, Luděk - Ševčíková, Sabina - Hajek, Roman
PY  - 2020
TI  - Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
JF  - European Journal of Haematology
VL  - 104
IS  - 3
SP  - 190-197
EP  - 190-197
PB  - Wiley-Blackwell
SN  - 09024441
KW  - cell-free DNA
KW  - liquid biopsy
KW  - multiple myeloma
KW  - qPCR
UR  - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358
L2  - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358
N2  - Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. Methods While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. Results We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. Conclusions These results support the concept of tumor-specific cell-free DNA as a prognostic marker.
ER  -

VRÁBEL, Dávid, Lenka SEDLARIKOVA, Lenka BESSE, Lucie ŘÍHOVÁ, Renata BEZDEKOVA, Martina ALMÁŠI, Veronika KUBACZKOVÁ, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Hana PLONKOVA, Tomas JELINEK, Viera SANDECKA, Martin STORK, Luděk POUR, Sabina ŠEVČÍKOVÁ and Roman HAJEK. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2020, vol.~104, No~3, p.~190-197. ISSN~0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13358.

Detailed Information on Publication Record